Dalgleish A G, Thomson B J, Chanh T C, Malkovsky M, Kennedy R C
Clinical Research Centre, Northwick Park Hospital, Harrow.
Lancet. 1987 Nov 7;2(8567):1047-50. doi: 10.1016/s0140-6736(87)91477-2.
Polyclonal anti-idiotypic antibodies were raised in mice against anti-Leu3a, a mouse monoclonal anti-human T4 (CD4) antibody that blocks the in-vitro binding of human immunodeficiency virus (HIV) to the CD4 molecule. The anti-idiotypes recognized anti-Leu3a but not OKT4, an anti-human T4 antibody that does not inhibit HIV binding to CD4. The anti-idiotypes specifically reacted with the HIV envelope glycoprotein in solid-phase immunoassays. More importantly, the anti-idiotypes neutralised three distinct isolates of HIV-1 and one isolate of HIV-2 in a syncytial inhibition assay. These results have implications for a potential AIDS vaccine of anti-CD4 preparations to induce an anti-idiotypic response with the capacity to bind HIV at its receptor site.
用小鼠制备了针对抗Leu3a的多克隆抗独特型抗体，抗Leu3a是一种小鼠单克隆抗人T4（CD4）抗体，可阻断人免疫缺陷病毒（HIV）在体外与CD4分子的结合。这些抗独特型抗体能识别抗Leu3a，但不能识别OKT4（一种不抑制HIV与CD4结合的抗人T4抗体）。在固相免疫测定中，这些抗独特型抗体能与HIV包膜糖蛋白发生特异性反应。更重要的是，在细胞融合抑制试验中，这些抗独特型抗体能中和三种不同的HIV-1分离株和一种HIV-2分离株。这些结果对于抗CD4制剂作为潜在的艾滋病疫苗诱导具有在HIV受体位点结合HIV能力的抗独特型反应具有重要意义。
